{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.02","upperLimit":"0.17","value":"0.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Grade 3-4 induction peripheral neuropathy rate was defined as the proportion of participants who experienced grade 3 or 4 peripheral neuropathy based on the Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAEv4) as reported on case report forms during induction therapy (4 cycles RsqVd for ASCT patients and 8 cycles for non-ASCT patients).","dispersionType":"90% Confidence Interval","groups":[{"description":"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m\\^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m\\^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.\n\nMaintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m\\^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy.","id":"OG000","title":"Lenalidomide, Subcutaneous Bortezomib, Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of all treated participants.","reportingStatus":"POSTED","timeFrame":"Participants were followed up to 24 weeks.","title":"Grade 3-4 Induction Peripheral Neuropathy Rate","type":"PRIMARY","unitOfMeasure":"proportion of participants"}